Hotbed/Location

Found 582,591 articles

• Todos Medical Enters Into COVID-19 PCR Testing Implementation and Equipment Financing Partnership with AID Genomics

  9/25/2020

  Todos Medical Ltd. (OTCQB: TOMDF), an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for the early detection of cancer and Alzheimer’s disease, today announced that it has entered into an implementation and equipment financing partnership with AID Genomics,

• Collegium Appoints Rita Balice-Gordon to its Board of Directors

  9/25/2020

  Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced the appointment of Rita Balice-Gordon to its Board of Directors, effective September 24, 2020.

• Endo Announces Fill-Finish Manufacturing and Services Agreement for Novavax COVID-19 Vaccine Candidate

  9/25/2020

  Endo International plc announced that its subsidiary, Par Sterile Products, LLC has entered into a non-exclusive agreement with Novavax, Inc. to provide fill-finish manufacturing services at its plant in Rochester, Michigan for NVX-CoV2373, Novavax' COVID-19 vaccine candidate.

• BioHiTech and the Hazleton Area School District to Introduce the District's New Altapure AP-4 Disinfectant System at the Hazle Township Early Learning Center on September 29, 2020

  9/25/2020

  BioHiTech Global, Inc. ("BioHiTech" or the "Company") (NASDAQ: BHTG), a sustainable technology and services company, announced today that the Company and the Hazleton Area School Distric

• Health Canada certifies Winnipeg Ventilator 2.0 for immediate distribution to support the needs of Covid-19 patients

  9/25/2020

  StarFish Medical announced that the Winnipeg Ventilator 2.0 has received a Health Canada COVID-19 Medical Device Authorization under the Interim Order Respecting the Importation and Sale of Medical Devices for Use in Relation to COVID-19 made by the Minister of Health on March 18, 2020.

• Cabaletta Bio to Present at Upcoming Investor Conferences in October

  9/25/2020

  Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Nichtberger, M.D., President and Chief Executive Officer, will present at the following three upcoming investor conferences in Octobe

• ALSA Ventures Closes US$59 Million European Biotech Venture Capital Fund

  9/25/2020

  ALSA Ventures today announced first closing of its European biotechnology investment fund with commitments of US$59M.

• REGENXBIO to Participate in Upcoming Investor Conferences - Sep 25, 2020

  9/25/2020

  REGENXBIO Inc., announced it will participate in the following upcoming investor conferences, which will each be held in a virtual meeting format:

• Catalyst Biosciences to Present at the Stifel Immunology and Inflammation Summit

  9/25/2020

  Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that Grant Blouse, Ph.D., senior vice president of translational research, will present at the Stifel Immunology and Inflammation Virtual Summit. Dr. Blouse will speak on a panel entitled: “The evolution of complement targeted therapies,” taking place on Thursday, October 1, 2020, at 9:00 AM Eastern Time

• Official Statement from Senator Dr. Richard Pan Regarding Anti-Vaxxers Influencing COVID Public Health Decisions

  9/25/2020

  On September 24, the Sacramento Bee reported that anti-vaccination extremists from outside of California prevented Placer County residents from expressing their views at a Supervisors' meeting and successfully influenced the Placer County Board of Supervisors' decision to rescind the county's emergency COVID order,

• Rakuten Medical Japan Announces Marketing Approval of Akalux® IV Infusion 250mg and BioBlade® Laser System from the Ministry of Labour, Health and Welfare in Japan for Locoregional Cancer Treatment

  9/25/2020

  Rakuten Medical Inc. is proud to announce that its wholly owned subsidiary Rakuten Medical Japan K.K. has received marketing approval in Japan from the Ministry of Health, Labour and Welfare for Akalux® IV Infusion 250mg (cetuximab saratolacan sodium) to treat unresectable locally advanced or recurrent head and neck cancer.

• Ortho Regenerative Technologies Reports its Second Quarter 2021 Results

  9/25/2020

  Closed non-brokered and oversubscribed Private Placements for total gross proceeds of $2.6 million, including $353,000 from management and Board members

• LB Pharmaceuticals Inc Secures $10.0 Million in Additional Financing

  9/25/2020

  LB Pharmaceuticals Inc, a biotechnology company focused on developing and commercializing novel and improved versions of successful CNS treatments, today announced the closing of a $10.0 million convertible note offering through a private placement to existing and new investors.

• Adial Pharmaceuticals Files for Expedited Review of AD04 with the FDA

  9/25/2020

  Adial Pharmaceuticals, Inc. today announced that it has submitted a formal request to the U.S. Food and Drug Administration (FDA) in support of that AD04 should be considered eligible for an FDA expedited review program.

• Happiness Biotech Announces $2.25 Million Private Placement In Support of Happy Buy

  9/25/2020

   Happiness Biotech Group Limited (the "Company" or Nasdaq: HAPP), an innovative China -based nutraceutical and dietary supplements producer, announced today that the Company has entered into certain securities purchase agreement with three non-U.S. investors, pursuant to which the Company agreed to sell 900,000 ordinary shares a

• FDA Approves Bausch + Lomb Alaway® Preservative Free (Ketotifen Fumarate) Ophthalmic Solution, 0.035%

  9/25/2020

  Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), Bausch + Lomb, a leading global eye health business, and Eton Pharmaceuticals, Inc. (NASDAQ: ETON) today announced that the U.S. Food and Drug Administration (FDA) has approved Alaway® Preservative Free (ketotifen fumarate) ophthalmic solution, 0.035%,

• Freeline to participate in Chardan’s 4th Annual Genetic Medicines Conference

  9/25/2020

  Freeline Therapeutics Holdings plc announced that Theresa Heggie, Chief Executive Officer, will present at the Chardan Virtual 4th Annual Global Healthcare Conference on October 6 at 4:45pm EDT.

• Verve Therapeutics to Present at the Jefferies Virtual Gene Therapy/Editing Summit

  9/25/2020

  Verve Therapeutics, a next-generation cardiovascular company, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will participate in the Jefferies Virtual Gene Therapy/Editing Summit being held October 1-2, 2020.

• FDA Approves KALYDECO® (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants With CF as Early as Four Months of Age

  9/25/2020

  Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved KALYDECO® (ivacaftor) for use in children with cystic fibrosis (CF) ages four months to less than six months old who have at least one mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to KALYDECO based on clinical and/or in vitro assay data.

• Decipher Biosciences Achieves Major Medicare Milestone with Expansion in Coverage for Decipher Prostate Genomic Testing

  9/25/2020

  First Precision Oncology Company to Receive Medicare Coverage for All Localized Prostate Cancer Patients Being Considered for Treatment   [25-September-2020]   SAN DIEGO , Sept. 25, 2020 /PRNewswire/ -- Decipher Biosciences, a commercial-stage precision oncology company committed to improving patient care, initially focused on urologic cancers, today announced that Palmet